United Therapeutics Corp (NASDAQ:UTHR) CEO Martine A. Rothblatt sold common stock totaling approximately $4.79 million on August 13, 2026. The sales followed the exercise of stock options for an equal number of shares. Rothblatt disposed of 9,500 shares of United Therapeutics common stock through a series of transactions on the reported date. The shares were sold at prices ranging from $499.46 to $512.64, with the total value received from these sales amounting to $4,790,316. The stock currently trades at approximately $500, reflecting a remarkable 60% gain over the past year.
These sales were preceded by Rothblatt's acquisition of 9,500 shares of common stock through the exercise of stock options, which were exercised at a price of $135.42 per share, representing a total value of $1,286,489.
The exercise of stock options and the subsequent sale of shares were carried out under a pre-arranged 10b5-1 trading plan, adopted by Rothblatt on November 7, 2025. This plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, all of which are set to expire on March 15, 2027.
Following these reported transactions, Rothblatt beneficially owns 324,443 shares indirectly through a family trust. She also holds other shares directly and indirectly through her spouse and various family trusts.
The company reported its second-quarter 2026 earnings, revealing earnings per share of $7.27, which surpassed Wall Street's estimate of $7.09. However, United Therapeutics experienced a revenue shortfall, posting $783.3 million against the anticipated $807.05 million. This revenue miss of approximately 2.9% has drawn significant attention from investors.
In response to these financial results, BofA Securities adjusted its price target for United Therapeutics, lowering it from $613 to $559, while maintaining a Neutral rating on the stock. The earnings report and subsequent analyst actions reflect mixed sentiment, with emphasis on the revenue miss despite the earnings beat.
Recent Developments in United Therapeutics Stock
United Therapeutics' stock has seen significant fluctuations in recent weeks, with the company's revenue miss and cautious sentiment surrounding its Tyvaso sales guidance contributing to the cautious sentiment.
CEO Rothblatt's Trading History
This is not the first time CEO Martine Rothblatt has sold shares of United Therapeutics stock. In June 2026, she sold $3.46 million worth of shares under the same 10b5-1 trading plan. The company's stock price has continued to rise despite these sales, reflecting the company's strong earnings performance.
Market Analysis
The mixed sentiment surrounding United Therapeutics' earnings report and the cautious sentiment surrounding its Tyvaso sales guidance reflect the complexity of the company's financial situation. Investors will be closely watching the company's future earnings and revenue performance to determine the direction of its stock price.
Conclusion
United Therapeutics' CEO Martine Rothblatt's recent sale of $4.79 million in stock reflects the company's strong earnings performance and the cautious sentiment surrounding its Tyvaso sales guidance. Investors will be closely watching the company's future earnings and revenue performance to determine the direction of its stock price.